Results 131 to 140 of about 10,157,624 (223)

Histopathology of nodal and extranodal non-hodgkin's lymphomas

, 2003
This volume - Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas - is an expanded and completely revised edition, now based on the WHO classification. The parallels to the updated Kiel classification and the REAL classification are indicated.
Le Tourneau A., PAULLI, MARCO, Diebold J, Feller Ac   +3 more
core  

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

British Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge, Lachlan Webb, Anita Pelecanos, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen‐Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Adrien Chauchet, Sylvain Choquet, Cédric Rossi, Adélie Herbin, Lukshe Kanagaratnam, Cyrielle Rodier, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Eliza A. Hawkes, Kirk Morris, Eric Durot, Joshua Tobin, Greg Hapgood   +25 more
wiley   +1 more source

Non-Hodgkin's lymphoma presenting as a retroperitoneal mass in the emergency department: a case report. [PDF]

Front Med (Lausanne)
Liu T, Zhao Y, Cui L, Liu H, Qu F.
europepmc   +1 more source

A non-randomised trial evaluating in-field control following the addition of involved-field radiotherapy to transplantation for patients with Hodgkin's Disease and non-Hodgkin's Lymphoma: An ALLG/TROG Prospective Multicentre Study (HDNHL04)

HeSANDA 1.0.0Dataset includes: Data for 45 patients with Hodgkin's Disease and non-Hodgkin's Lymphoma, assessing the addition of radiotherapy as part of the transplant treatment.

core   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

ESHAP versus IEV Chemotherapy for Relapsed or Refractory Hodgkin's and Non-Hodgkin's Lymphoma. [PDF]

Int J Hematol Oncol Stem Cell Res
Dehghani M, Vojdani R, Khalafi-Nezhad A, Ravanbod MR, Ramzi M, Dehdashti S, Taherifard E, Namdari N.   +7 more
europepmc   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

CNS Non-Hodgkin's Lymphoma With Atypical T2 Hyperintensity and Necrosis Mimicking Glioblastoma Multiforme: A Radiological Enigma. [PDF]

Cureus
Haroon Ahmed M, Mohammed Abdul M, Nadeem A, Yaratapally N, Abid M, Mohammad AM, Ali MAM, Athmakuri KS, Mohammed OF, Bhadra T.   +9 more
europepmc   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Network structure of depression, anxiety and stress in patients with non-Hodgkin's lymphoma receiving chemotherapy: a multicentre cross-sectional study. [PDF]

BMJ Open
Wang Y, Liu X, Xu XJ, Gu J.
europepmc   +1 more source